ES014

DRUG4 trials

Sponsors

Elpiscience Biopharma, Ltd., Elpiscience (Suzhou) Biopharma, Ltd., Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Conditions

Advanced Solid TumorDesmoid TumorLocally Advanced Solid TumorMetastatic Solid TumorSolid Tumor

Phase 1

A Study of ES014 (Anti-CD39/TGF-β Bispecific Antibody) in Patients With Locally Advanced or Metastatic Solid Tumors

WithdrawnNCT05381935

Elpiscience Biopharma, Ltd.Advanced Solid Tumor

Start: 2023-04-21End: 2026-04-30Updated: 2023-01-31

A Study of ES014 in Patients With Locally Advanced or Metastatic Solid Tumours

Active, not recruitingNCT05717348

Elpiscience (Suzhou) Biopharma, Ltd.Locally Advanced Solid Tumor, Metastatic Solid Tumor, Solid Tumor

Start: 2023-02-24End: 2027-02-28Target: 120Updated: 2025-08-13

Phase 2

A Study of ES014 in Subjects With Advanced Solid Tumors

RecruitingNCT06543056

Cancer Institute and Hospital, Chinese Academy of Medical SciencesAdvanced Solid Tumor

Start: 2024-11-25End: 2026-09-30Target: 15Updated: 2025-07-30

A Study in Adults With Desmoid Tumors

RecruitingNCT07541430

Elpiscience (Suzhou) Biopharma, Ltd.Desmoid Tumor

Start: 2026-04-30End: 2028-10-01Target: 50Updated: 2026-04-30